Found: 14
Select item for more details and to access through your institution.
Treatment with low‐dose, single‐agent belantamab mafodotin is safe and provides long‐term responses in heavily pretreated multiple myeloma patients.
- Published in:
- European Journal of Haematology, 2024, v. 112, n. 3, p. 367, doi. 10.1111/ejh.14120
- By:
- Publication type:
- Article
Response rates of extra‐nodal diffuse large B cell lymphoma to anti‐CD19‐CAR T cells: A real word retrospective multicenter study.
- Published in:
- European Journal of Haematology, 2023, v. 111, n. 1, p. 63, doi. 10.1111/ejh.13968
- By:
- Publication type:
- Article
Vagal Nerve Activity Predicts Prognosis in Diffused Large B-Cell Lymphoma and Multiple Myeloma.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 3, p. 908, doi. 10.3390/jcm12030908
- By:
- Publication type:
- Article
Real‐world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study.
- Published in:
- British Journal of Haematology, 2023, v. 200, n. 1, p. 45, doi. 10.1111/bjh.18479
- By:
- Publication type:
- Article
Lymphoproliferative disease detected by breast cancer screening.
- Published in:
- Journal of Medical Screening, 2022, v. 29, n. 4, p. 255, doi. 10.1177/09691413221109988
- By:
- Publication type:
- Article
BNT162b2 mRNA COVID‐19 vaccine booster induces seroconversion in patients with B‐cell non‐Hodgkin lymphoma who failed to respond to two prior vaccine doses.
- Published in:
- British Journal of Haematology, 2022, v. 196, n. 6, p. 1329, doi. 10.1111/bjh.18029
- By:
- Publication type:
- Article
[<sup>18</sup>F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2022, v. 49, n. 3, p. 953, doi. 10.1007/s00259-021-05551-5
- By:
- Publication type:
- Article
Low FXIII activity levels in intensive care unit hospitalized COVID-19 patients.
- Published in:
- Thrombosis Journal, 2021, v. 19, n. 1, p. 1, doi. 10.1186/s12959-021-00333-3
- By:
- Publication type:
- Article
Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma.
- Published in:
- British Journal of Haematology, 2021, v. 195, n. 2, p. 186, doi. 10.1111/bjh.17608
- By:
- Publication type:
- Article
Daratumumab for relapsed AL amyloidosis—When cumulative real‐world data precedes clinical trials: A multisite study and systematic literature review.
- Published in:
- European Journal of Haematology, 2021, v. 106, n. 2, p. 184, doi. 10.1111/ejh.13535
- By:
- Publication type:
- Article
Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life Study.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Bortezomib washout duration prior to stem cell mobilization in patients with newly diagnosed multiple myeloma.
- Published in:
- European Journal of Haematology, 2020, v. 105, n. 1, p. 30, doi. 10.1111/ejh.13404
- By:
- Publication type:
- Article
Cryoablative Surgery for Patients with Radiotherapy Resistant Solitary Plasmacytoma: Report of Two Cases.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e191, doi. 10.1016/j.clml.2019.09.320
- By:
- Publication type:
- Article
Outcomes of Post-Induction Bortezomib Therapy in Patients with Newly diagnosed Multiple Myeloma: A Multi-Center Retrospective Observational Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e296, doi. 10.1016/j.clml.2019.09.486
- By:
- Publication type:
- Article